|4Dec 19, 5:38 PM ET

Goncalves Joana 4

4 · Oruka Therapeutics, Inc. · Filed Dec 19, 2025

Insider Transaction Report

Form 4
Period: 2025-12-19
Goncalves Joana
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-19$6.84/sh+3,500$23,9405,018 total
  • Exercise/Conversion

    Common Stock

    2025-12-19$7.80/sh+3,500$27,3008,518 total
  • Sale

    Common Stock

    2025-12-19$28.53/sh641$18,2897,877 total
  • Sale

    Common Stock

    2025-12-19$29.62/sh1,787$52,9356,090 total
  • Sale

    Common Stock

    2025-12-19$30.70/sh1,492$45,8064,598 total
  • Sale

    Common Stock

    2025-12-19$31.58/sh3,080$97,2631,518 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2025-12-193,500225,063 total
    Exercise: $6.84Exp: 2034-05-06Common Stock (3,500 underlying)
  • Exercise/Conversion

    Employee Warrant (right to buy)

    2025-12-193,500196,492 total
    Exercise: $7.80Exp: 2034-07-14Common Stock (3,500 underlying)
Footnotes (8)
  • [F1]Includes 191 shares acquired under the Oruka stock purchase plan on December 8, 2024, 661 shares acquired under the Oruka stock purchase plan on June 8, 2025 and 666 shares acquired under the Oruka stock purchase plan on December 8, 2025.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 to $29.12, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5) and (6) to this Form 4.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $30.13, inclusive.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.18, inclusive.
  • [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $32.00, inclusive.
  • [F7]The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
  • [F8]The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES